Previous Article | Next Article ![]()
Molecular and Cellular Biology, January 2006, p. 413-424, Vol. 26, No. 2
0270-7306/06/$08.00+0 doi:10.1128/MCB.26.2.413-424.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Department of Microbiology,1 Department of Oncological Sciences, Mount Sinai School of Medicine, New York, New York 10029,4 Department of Molecular and Cellular Oncology,2 Department of Radiation Oncology, M. D. Anderson Cancer Center, University of Texas, Houston, Texas 77030,3 Signal Transduction Program, The Burnham Institute, La Jolla, California 920375
Received 21 April 2005/ Returned for modification 3 June 2005/ Accepted 20 October 2005
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
-subunits and two transmembrane ß-subunits (33, 57). IR mediates prenatal growth in response to IGF-II (22) and postnatal homeostasis of glucose metabolism in response to insulin (33), while IGF-1R mediates IGF-1 and IGF-II action on prenatal growth and IGF-1 action on postnatal growth, as well as a variety of physiological functions (1, 40). Dysregulation of IR- or IGF-1R-mediated signaling has been linked to oncogenic properties of transformed and cancer cells (11, 24, 27, 39, 56). Activation of IR and IGF-1R upon cognate ligand binding results in activation of different downstream signaling pathways including those of mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) through adaptors like insulin receptor substrate (IRS), Grb2, and Shc family proteins (5, 7, 13, 20, 21, 48, 49, 50, 56, 59, 60). Other substrates of IR and IGF-1R include phospholipase C proteins and signal transducers and activators of transcription (STATs) (15, 34, 51, 63). Furthermore, IR- and IGF-1R-activated signaling cross-talks via mediators such as IRS1, Shc, PI3K, and receptor for activated C kinase 1 (RACK1) with that of integrin, resulting in so-called inside-out signaling (56). STATs comprise a family of transcriptional factors and are important in embryonic development, organ genesis, and innate and adaptive immune function, as well as regulation of cell growth, differentiation, and apoptosis (10). A large number of cytokines and growth factors, including insulin and IGF-1, can trigger STAT activation. Constitutive or elevated activation of STAT3 and/or STAT5 has been implicated in development of a variety of tumors (6, 9, 10). STAT5 and STAT3 can be activated through IR and IGF-1R (15, 17, 51, 63). JAK family kinases are involved in IR-mediated STAT5 and IGF-1R-mediated STAT3 activation (38, 63). However, the question whether STATs directly bind to the receptor protein tyrosine kinases (RPTKs) or are mediated via adaptors for their recruitment to the receptors remains open. The IR mutant unable to bind and activate STAT5 (38) was still able to activate STAT3 (our unpublished observations). No consensus STAT3 binding site was found in IGF-1R. Therefore, it suggested to us that IR/IGF-1R might mediate activation of STAT3 via an adaptor.
RACK1 was found to associate with STAT1 constitutively, enhancing interferon-mediated antiviral functions through interaction with JAK family kinases (28, 37, 54); thus, it may be a candidate for IR/IGF-1R-mediated STAT3 binding and activation. RACK1 was originally identified as a receptor for activated C kinases and is a member of the family of seven WD40-motif-containing proteins (45). RACK1 is predicted to be a scaffold protein with three dozen or so known interacting partners and has been implicated in regulating diverse biological functions (44). RACK1 is involved in regulating tyrosine kinase-mediated signaling, including Src (12, 43), IR and IGF-1R (30, 36), and JAKs (28). RACK1 was also upregulated in lung, colon, and breast carcinoma cells (2). We observed that a significant fraction of RACK1 is relocated from cytoplasm to membrane in different oncogene-transformed mammalian and avian cells (30). All these observations suggest that RACK1 regulates signaling pathways involved in transformation.
We hypothesized that RACK1 may function as an adaptor protein in the IR/IGF-1R-mediated STAT3 signaling pathway. We found that RACK1 regulated IR/IGF-1R-mediated STAT3 activation specifically by recruiting STAT3 to the receptors, which plays an important role in the colony forming ability of certain ovarian cancer cells.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Plasmids and their construction. phEF-RACK1-HA (where EF is elongation factor and HA is hemagglutinin) (30), phEF-IGFR (63), phEF-IR (38), EGFR, and EGFR-Ros (61) chimeras have been described previously. The pCMV-STAT3 and pCMV-dnSTAT3 were kindly provided by James Darnell, Jr., and Curt Horvath and have been described elsewhere (31). phEF-HA-WD1-4 and phEF-HA-WD5-7, containing the WD domains 1 to 4 (residues 1 to 180) and 5 to 7 (residues 180 to 317), respectively, of RACK1, were generated by PCR amplification of the corresponding fragments and cloned into the BamHI-NotI sites of the phEF-Neo plasmid. IGF-1R S1248A and IR S1275A were generated by using a QuikChange site-directed mutagenesis kit (Stratagene) and were confirmed by DNA sequencing. RACK1, WD1-4, and WD5-7 were subcloned into bacteria-expressing vector pTAT with a six-His tag for Ni-nitrilotriacetic acid (NTA) purification. STAT3 and IR/IGF-1R cytoplasmic domains were cloned into the SalI-NotI sites of pGEX6p-1 for glutathione transferase (GST) fusion protein preparation and purification.
Antibodies. Anti-STAT3pY705, anti-pErk1/2, anti-Erk1/2, anti-pAkt, and anti-Akt antibodies were purchased from Cell Signaling. Anti-STAT3 was purchased from Santa Cruz. Anti-RACK1, anti-pY20HRPO (where HRPO is horseradish peroxidase), goat anti-rabbit HRPO, and goat anti-mouse HPRO were purchased from Transduction Laboratories. anti-EGFR antibody was purchased from Oncogene Science. Antitubulin, anti-His, rabbit anti-mouse secondary antibody, and anti-c-Myc antibodies were purchased from Sigma. Anti-IR (15), anti-IGFR (41), and anti-Ros (32) were described previously. Anti-HA epitope was purchased from Hybridoma Center of Mount Sinai. Anti-snRNP was a gift from Serafin Pinol-Roma.
Protein purification and in vitro binding assay. His-tagged TAT-RACK1 and mutants were purified with Ni-NTA agarose (QIAGEN). GST-STAT3, GST-IRKD (where KD is kinase domain), and GST-IGFRKD were purified with glutathione-Sepharose beads (Amersham). An in vitro binding assay was performed in NP-40 lysis buffer (20 mM HEPES, pH 7.4, 150 mM NaCl, 1% NP-40, 10% glycerol, 1 mM EDTA, pH 8.0, 1 mM phenylmethylsulfonyl fluoride, 1% aprotinin). Indicated amounts of proteins were combined in NP-40 lysis buffer and gently rotated at 4°C overnight, followed by the addition of 20 µl of Ni-NTA agarose or 10 µl of glutathione-Sepharose beads for 1 h. Beads were recovered by gentle centrifugation at 3,000 x g for 3 min and washed twice with NP-40 lysis buffer. Samples were boiled in sodium dodecyl sulfate (SDS)-loading buffer.
Preparation of cell lysates, immunoprecipitation, SDS-PAGE and immunoblotting. For direct Western analysis, cell lysates were prepared with ice-cold radioimmunoprecipitation assay buffer (50 mM Tris-Cl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 1% deoxycholate, 5 mM EDTA, 1% aprotinin, 1 mM phenylmethylsulfonyl fluoride, 0.4 mM phenylarsine oxide, and 25 mM NaF). For coimmunoprecipitation, cell lysates were extracted with NP-40 lysis buffer as described above. Cell lysates or immunoprecipitates were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting with indicated antibodies.
Velocity sedimentation on glycerol gradient. HEK 293T cells were transiently transfected with 600 ng of IR and STAT3 in 10-cm dishes, followed by serum starvation for 24 h and insulin stimulation for 15 min. Cell lysates were prepared and loaded onto a 20 to 40% glycerol gradient in NP-40 lysis buffer. Centrifugation was done in an SW40 Ti rotor (Beckman) at 38,000 rpm for 66 h, and fractions were collected from the bottom. Proteins from gradient fractions or immunoprecipitates from the selected fractions with anti-RACK1 antibody were separated by SDS-PAGE, followed by immunoblotting with indicated antibodies.
RNA interference. Templates of small interfering RNA (siRNA) against RACK1 were designed according to the instructions in the Silencer siRNA Construction kit (Ambion Inc.) and synthesized (Invitrogen). In vitro transcription and formation of double-strand siRNA were performed according to the protocol provided with the kit. Sequences of the siRNA1 templates are 5'-AAGCAAGAAGTTATCAGTACCCCTGTCTC (sense) and 5'-AAGGTACTGATAACTTCTTGCCCTGTCTC (antisense). Sequences for the scrambled control for siRNA1 are 5'-CACAAGTCGAAACGTAAATGTCCTGTCTC (sense) and 5'-ACATTTACGTTTCGACTTGTGCCTGTCTC (antisense). Sequences of the siRNA2 templates are 5'-AACTATGGAATTCCACAGCGTCCTGTCTC (sense) and 5'-AAACGCTGTGGAATTCCATAGCCTGTCTC (antisense). pRS-shRNA, containing the RACK1 sequence as a template for shRNA construction, has been previously described (42).
Reporter assay. HEK 293T cells were transfected with 150 ng of phEF-IR, 50 ng of pCMV-STAT3, and 250 ng of phEF-Neo or RACK1, along with 50 ng of pRL-TK and 50 ng of TKS3 (53) (STAT3 reporter construct); NIH 3T3/IR cells were transfected with 50 ng of pRL-TK, and 150 ng of 3xLy6E (31) (a STAT3 reporter construct containing three Ly6E sites), together with 1 µg of phEF-Neo or RACK1 or together with siRNA or scrambled control (10 nM). After 24 h (for RACK1 or phEF-neo) or 96 h (for siRNA or scrambled control), cells were serum starved for 12 h and then stimulated with insulin for 6 h. Luciferase activity was measured by a dual-luciferase reporter assay kit from Promega.
Colony formation assay, anoikis assay, and migration and invasion assays. At 48 h posttransfection, transfected PA-1, SW626, and SKOV3 cells were trypsinized, counted, and resuspended. A total of 2.5 x 105 PA-1, 105 SW626, and 105 SKOV3 cells were used for colony formation assays with or without the addition of insulin and IGF-1 as previously reported (30); 105 cells were used for the migration and invasion assays (3). At 24 h posttransfection, NIH 3T3 cells were starved overnight, followed by insulin or IGF-1 treatment for 10 h. Anoikis assays were carried out as described previously (55).
| RESULTS |
|---|
|
|
|---|
) receptor (37, 54) and shown to associate with IR and IGF-1R and to regulate IR- and IGF-1R-mediated signaling functions (30, 35, 36). To investigate whether RACK1 is involved in IR- and IGF-1R-mediated signaling pathways, HEK 293T cells were transiently transfected with phEF-IR (Fig. 1A and E) or phEF-IGF-1R (Fig. 1D), STAT3, and phEF-neo or RACK1. Overexpression of RACK1 in HEK 293T cells significantly enhanced insulin- and IGF-1-mediated STAT3 phosphorylation (Fig. 1A, D, and E), suggesting that RACK1 played an important role in IR/IGF-1R-STAT3 activation, which appeared to be receptor specific since RACK1 failed to enhance fetal calf serum-induced STAT3 activation (Fig. 1A). Receptor specificity was further confirmed since overexpression of RACK1 could not enhance STAT3 activation mediated by EGFR (see Fig. S1A in the supplemental material) or EGFR-Ros chimeras (see Fig. S1B and C in the supplemental material) (61). In agreement with the above results, the overexpression of RACK1 in NIH 3T3/IR cells, murine embryonic fibroblasts stably overexpressing human IR (Fig. 1B and F), or the introduction of TAT-his-RACK1 (TAT is a positively charged peptide from human immunodeficiency virus type 1 that can facilitate protein entry into living cells[29]) into Mewo cells, a human melanoma cell line (Fig. 1C), also enhanced insulin-induced endogenous STAT3 activation. RACK1-mediated STAT3 activation through IR was specific since RACK1 could not affect insulin-induced phosphorylation levels of IR, Akt, and MAPK in HEK 293T and NIH 3T3/IR cells (Fig. 1A, B, E, and F).
|
|
|
|
To determine which region of RACK1 is responsible for its interaction with STAT3 and IR/IGF-1R, truncation mutants of RACK1 were constructed. Both IR and STAT3 were coimmunoprecipitated with HA-RACK1 and the 3' deletion mutant HA-WD1-4 (amino acids 1 to 180) but not with the 5' deletion mutant HA-WD5-7 (amino acids 181 to 317) (Fig. 4C). The association indicates that interaction between RACK1 and IR or STAT3 is not due to nonspecific interaction by HA-tagged protein. This result suggests that the WD1-4 domain is sufficient to interact with IR and STAT3 and enhance the IR-mediated STAT3 activation (see Fig. S3 in the supplemental material).
To detect the triple complex formation of IR, STAT3, and RACK1, glycerol gradient sedimentation was performed to examine the distribution patterns of IR, STAT3, and RACK1 proteins with or without insulin induction in HEK 293T cells. The results of immunoblotting analysis revealed that STAT3 or RACK1 had broad distribution along the glycerol gradient, peaking between fractions 16 to 18, while IR only appeared in fractions 9 to 15 with a peak at fractions 13 to 14. Insulin induction did not shift the gross distribution patterns of all three proteins (see Fig. S4 in the supplemental material). However, IR was coimmunoprecipitated with RACK1 protein upon insulin induction, which further supports the results shown in Fig. 3; the IR peak shifted to the heavier sedimentation fraction 12 (Fig. 4D). STAT3 associated with RACK1 constitutively (Fig. 3A and C and 4D); however, insulin stimulation led to the accumulation of STAT3/RACK1 complexes to the faster sedimentation fractions 12 to 15, with a peak at fraction 12 (Fig. 4D), corresponding to the IR peak coimmunoprecipitated with RACK1. The result supports the insulin-inducible triple protein complex formation of IR, RACK1, and STAT3 and strengthens our hypothesis that RACK1 recruits STAT3 to IR for activation.
To test if RACK1 can interact with IR, IGF-1R, and STAT3 directly, in vitro binding assays were carried out with GST-STAT3, GST-IRKD (containing IR cytoplasmic domain), GST-IGFRKD (containing IGF-1R cytoplasmic domain), and His-tagged RACK1 or its truncation mutants. All the fusion proteins were expressed and purified from Escherichia coli, except that IRKD was also expressed in insect cells. His-RACK1 could pull down IR kinase domain expressed in insect cells (4) in a dose-dependent manner (Fig. 5A). His-RACK1 directly interacted with GST-STAT3, GST-IRKD, and GST-IGFRKD but not with GST (Fig. 5B). His-RACK1 and WD1-4, but not WD5-7, were able to associate with GST-STAT3, GST-IRKD, and GST-IGFRKD (Fig. 5C, D, and E). These data support the intracellular association of the proteins described above and suggest that RACK1 could interact directly with IR, IGF-1R, and STAT3.
|
, FAK, and p130cas, were unaffected compared to the wild-type receptors (Fig. 6A to D and data not shown). Our data demonstrate that the association between RACK1 and IR/IGF-1R is important for the receptor-mediated recruitment and activation of STAT3 specifically.
|
c-myc is an important STAT3 target proto-oncogene (6, 9, 10) in the regulation of cell cycle progression and proliferation; vegf is another STAT3 target gene involved in angiogenesis (46). Overexpression of RACK1 enhanced insulin-induced c-myc mRNA (Fig. 7A) and protein (Fig. 7B) in HEK 293T cells and IGF-1 induced vegf mRNA in SKOV3 cells. The enhancement was dependent on STAT3 because dominant negative STAT3 (dnSTAT3, defective in DNA binding and shown to be able to block the wild-type STAT3 activation [31]) greatly reduced the RACK1-mediated enhancement of insulin-induced c-myc mRNA (Fig. 7A) and IGF-1-induced vegf mRNA (Fig. 7C). The expression of IGF-1-induced vegf gene in SKOV3 cells was also dependent on endogenous RACK1 since downregulation of RACK1 expression by two independent siRNAs significantly reduced IGF-1-induced vegf gene expression (Fig. 7C). Overexpression of RACK1 significantly augmented insulin-induced transcription of the STAT3-specific reporter gene in both HEK 293T and NIH 3T3 cells (Fig. 7D and E). Downregulation of RACK1 by siRNA significantly decreased insulin-induced STAT3-specific reporter gene expression in NIH 3T3 cells, suggesting that RACK1 specifically regulates the IR/IGF-1R-mediated STAT3 phosphorylation and activation of its transcriptional activity and target gene expression.
|
A panel of human ovarian cancer cell lines was screened for the expression of RACK1 and found to express various levels of RACK1 (data not shown). Three lines, PA-1, SW626, and SKOV3, with high and low RACK1 expression levels and with moderate to high levels of expression of IR/IGF-1R and STAT3 were chosen for further analysis (see Fig. S6A in the supplemental material). PA-1 and SW626 cells had a relatively high level of RACK1. Insulin and IGF-1 promoted a 2.5-fold increase of colony formation in PA-1 cells, which was further enhanced by about 40% upon overexpression of RACK1 (Fig. 8A). Overexpression of RACK1 had only a small effect on promoting insulin- and IGF-1-stimulated colony formation of SW626 cells (Fig. 8A). However, reducing the RACK1 level by twofold using siRNA in PA-1 and SW626 cells (Fig. 8B) greatly reduced the insulin- and IGF-1-induced colony forming ability of the cells (Fig. 8A). The control siRNA had no significant effect. Introduction of dnSTAT3 together with RACK1 into PA-1 and SW626 cells neutralized the enhancing effect of RACK1 and further reduced the insulin- and IGF-1-induced colony forming ability of the cells (Fig. 8A). SKOV3 cells had a relatively low level of RACK1 (see Fig. S6A in the supplemental material). Overexpression of RACK1 resulted in a twofold enhancement of the insulin- and IGF-1-induced colony forming ability of the cells (Fig. 8A). Similarly, introduction of the dnSTAT3 together with RACK1 into SKOV3 cells neutralized the effect of RACK1 and further reduced the colony forming ability to a level similar to that of dnSTAT3 alone (Fig. 8A). The tyrosine phosphorylation level of STAT3 was consistent with overexpression or reduction of RACK1 in the three cancer lines, with the exception of RACK1 overexpression in SW626 cells (Fig. 8B). This could be due to the fact that SW626 cells have a relatively high level of RACK1, which is more than sufficient to mediate activation of a relatively low level of STAT3 (see Fig. S6A in the supplemental material). The differential response of the three lines toward dnSTAT3 could be due to different STAT3 expression levels in the cells; SW626, with a lower expression level of STAT3, was more sensitive to dnSTAT3, while PA-1, with a higher level of STAT3 than SW626 and SKOV3 cells, was relatively more resistant to dnSTAT3 (see Fig. S6A in the supplemental material). Unlike anchorage-independent growth, RACK1 was also able to enhance the migration and invasion activity of PA-1 cells; dnSTAT3 was unable to reverse the effect of RACK1 (see Fig. S6B in the supplemental material).
|
The above results are consistent with the notion that RACK1 functions upstream of STAT3 in the IR/IGF-1R-STAT3 signaling pathway, which appears to be more important for anchorage-independent growth and survival than for migration and invasion under those conditions.
| DISCUSSION |
|---|
|
|
|---|
RACK1 regulates IR/IGF-1R-mediated STAT3 activation in a receptor-specific and pathway-specific manner. The basis for the specificity could be due to specific interaction between RACK1 and IR or IGF-1R. Apparently, EGFR and Ros are able to activate STAT3 independent of RACK1. However, we cannot rule out the possibility that RACK1 may mediate STAT3 activation in certain other RPTKs. The RACK1 expression level did not affect other IR/IGF-1R-mediated signaling pathways in HEK 293T (Fig. 1A and E), NIH 3T3/IR (Fig. 1B and F), Mewo (Fig. 2B), SKOV3 (Fig. 2C), and SW626 (data not shown) cells, although Kiely et al. reported that overexpression of RACK1 in an IGF-1R reconstituted mouse cell line (R+) and in the human breast cancer line MCF7 cells resulted in enhanced IGF-1-induced MAPK activation but decreased Akt activation (36). We partially confirmed their results concerning the effect of RACK1 on IGF-1-induced activation of MAPK by either overexpression or repression of RACK1 in MCF7 cells but failed to see the change in Akt activation. The reason for the paradox between the observation of Kiely et al. and ours is still unclear; however, it may be cell type dependent or relevant to the IGF-1R and RACK1 expression levels in the MCF7 cells. The observed augmenting effect of RACK1 on IGF-1-induced MAPK activation (36) could be due to an indirect mechanism, for example, mediated by RACK1/protein kinase C (PKC). Nevertheless, among the six independent cell lines tested, we only observed a partial effect of RACK1 on IGF-1-induced MAPK activation in MCF7 cells (data not shown).
Our current data confirm the interaction of RACK1 and IR reported by Kiely et al. (36). The failure to observe such interaction in our previous study (30) was apparently due to the nonoptimal combination of detergent and the antibody used, as demonstrated in Fig. S2 in the supplemental material. However, failure to detect the IR/RACK1 interaction in a yeast two-hybrid assay previously (30) remains puzzling. One possibility is that the cytoplasmic domain of IR used as bait in that assay could inadvertently harbor a mutation affecting RACK1 binding but not that of STAT5 used as a positive control (30).
In MCF7 and R+ cells, Kiely et al. reported that association of RACK1 with IR and IGF-1R was constitutive (36). Although we also observed a basal level of association, our data show that association of RACK1 with IR and IGF-1R is significantly augmented by ligand stimulation at a low level of RACK1 expression and that the association becomes constitutive beyond a certain threshold of RACK1 expression, in agreement with our previous observation (30). The expression level of RACK1 seems to be critical for the pattern of interaction between IR or IGF-1R and RACK1, as well as for the interaction between STAT3 and IR, suggesting that the concentration of RACK1 around the receptors is a determining factor of the association. The binding of endogenous RACK1 to IGF-1R in HEK 293T cells shifted from being inducible to constitutive upon increasing the level of HA-RACK1 (Fig. 4B), which may be explained by heterodimerization between HA-RACK1 and endogenous RACK1 (52) or by competition for cytosolic localization. The interaction between IR and STAT3 is dramatically enhanced by overexpression of RACK1 and decreased by downregulation of RACK1 expression (Fig. 2A and 4A). These observations and the constitutive association between STAT3 and RACK1 (Fig. 3A and C and 4D) support our hypothesis that RACK1 forms a constitutive complex with STAT3 in cytosol, which is recruited to the IR/IGF-1R specifically, subsequent to the activation of receptors (Fig. 8E).
WD1-4 of RACK1 is responsible for the IGF-1R/IR and STAT3 binding. Based on the amino acid similarity and Gß crystal structure (58), RACK1 was predicted as a seven-bladed propeller Gß-like structure with significant differences in the sixth and seventh WD domains, which are required for interaction with different proteins including PKCß, PDE4D5, Src, and ß-integrin (44); by contrast, IR, IGF-1R, and STAT3 seem to interact with WD1-4 of RACK1. The predicted structure of WD1-4 is quite similar to that of the Gß subunit. The finding that Gß can also bind to IGF-1R and RACK1 (16, 19) is consistent with our result. It would be interesting to see if Gß plays a role similar to that of RACK1 in recruiting other signaling effectors of IGF-1R.
RACK1 may form a platform in IR/IGF-1R-mediated STAT3 signaling. Triple protein complexes of IR, STAT3, and RACK1 were formed upon insulin stimulation of IR as shown in a glycerol sedimentation assay. It remains a possibility that RACK1 could recruit other molecules involved in STAT3 activation including JAK family kinases and Ser/Thr kinases. We have shown that JAKs play a positive role in IR-mediated STAT5 and STAT3 activation and IGF-1R-mediated STAT3 activation (38, 63 and data not shown). JAKs were reported to interact with RACK1, contributing to IFN-
-mediated STAT1 activation (28). It is possible that RACK1 could also recruit JAKs for IR/IGF-1R-mediated STAT3 activation. Other STAT3 regulators including PKC family kinases and MAPKs have been reported to be involved in the phosphorylation and activation processes of STAT3 upon different stimuli (23). We did find that serine 727 phosphorylation of STAT3 was also enhanced by overexpression of RACK1 (data not shown), but the mechanism for this enhanced phosphorylation is not clear at the present time. In this regard, our previous finding that IGF-1 induces increased association of IGF-1R with PKC
and PKCµ as well as association of RACK1 and PKCµ is interesting. It will be worthwhile to further investigate the role of RACK1 in the IGF-1-induced interaction between IGF-1R and PKCs.
The IR/IGF-1R-RACK1-STAT3 pathway regulates oncogenic properties of certain ovarian cancer cells. STAT3 was found to be important in regulating anchorage-independent growth (55). The function of RACK1 in IGF-1R-mediated mitogenic effect appears to depend on the type of cells (30, 36). Overexpression of RACK1 was able to significantly enhance the insulin- and IGF-1-promoted anchorage-independent growth of PA-1 and SKOV3 cells (Fig. 8A). It was suggested that the reasons for the diverse effect of RACK1 on the growth in different cell systems could be due to the possibility that fibroblasts and transformed epithelial cells differ significantly with regard to integration and cross talk between adhesion molecule-mediated and growth factor receptor-mediated signaling (47). Another possible reason for the differential effect of RACK1 on cell growth may be the cellular localization of RACK1. RACK1 was redistributed to the membrane in several oncogene-transformed (including oncogenic IGF-1R and IR) mammalian and avian cells (30), which may allow RACK1 to regulate mitogenic signaling more effectively from the plasma membrane. In mouse fibroblasts, RACK1 is located mostly to the cytoskeleton with a certain amount in the cytoplasm (30); thus, it may sequester certain molecules from reaching the membrane. The role of RACK1 in regulating various oncogenic properties of cancer cells may be the sum of the multifaceted effect of RACK1 in various signaling pathways including the IR/IGF-1R-STAT3 signaling demonstrated previously (30, 35, 36) and in the present study as well as the PKC/JNK pathway mediated by RACK1 (42). Overexpression of RACK1 enhances stress fibers, focal adhesions, and membrane protrusion, and the opposite is true by its depletion (30). Accordingly, RACK1 is expected to play a role in regulating cell migration. However, the limited reports on the effect of RACK1 on migration are controversial (3, 8, 18). The reason for the different effects of RACK1 on migration in those cells is currently unknown.
In conclusion, RACK1 acts as an adaptor protein to facilitate the association of STAT3 with IR/IGF-1R and subsequent phosphorylation and activation of STAT3 specifically. In this fashion, RACK1 plays an important role in IR/IGF-1R-mediated promotion of anchorage-independent growth of certain ovarian cancer cells.
| ACKNOWLEDGMENTS |
|---|
We thank Steven Dowdy for providing pTAT vector; Ronald Kohanski for the gift of the IRKD-expressing insect cells; C. Horvath, J. Darnell, and R. Jove for the dnSTAT3 mutant and reporter plasmids; and Joseph Chan for discussion.
| FOOTNOTES |
|---|
Supplemental material for this article may be found at http://mcb.asm.org/. ![]()
| REFERENCES |
|---|
|
|
|---|
2. Berns, H., R. Humar, B. Hengerer, F. N. Kiefer, and E. J. Battegay. 2000. RACK1 is up-regulated in angiogenesis and human carcinomas. FASEB J. 14:2549-2558.
3. Besson, A., T. L. Wilson, and V. W. Yong. 2002. The anchoring protein RACK1 links protein kinase C
to integrin ß chains. Requirements for adhesion and motility. J. Biol. Chem. 277:22073-22084.
4. Bishop, S. M., J. B. Ross, and R. A. Kohnaski. 1999. Autophosphorylation dependent destabilization of the insulin receptor kinase domain: trytophan-1175 reports changes in the catalytic cleft. Biochemistry 38:3079-3089.[CrossRef][Medline]
5. Blenis, J. 1993. Signal transduction via the MAP kinases: proceed at your own RSK. Proc. Natl. Acad. Sci. USA 90:5889-5892.
6. Bowman, T., R. Garcia, J. Turkson, and R. Jove. 2000. STATs in oncogenesis. Oncogene 19:2474-2488.[CrossRef][Medline]
7. Brunet, A., A. Bonni, M. J. Zigmond, M. Z. Lin, P. Juo, L. S. Hu, M. J. Anderson, K. C. Arden, J. Blenis, and M. E. Greenberg. 1999. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell 96:857-868.[CrossRef][Medline]
8. Buensuceso, C. S., D. Woodside, J. L. Huff, G. E. Plopper, and T. E. O'Toole. 2001. The WD protein Rack1 mediates protein kinase C and integrin-dependent cell migration. J. Cell Sci. 114:1691-1698.[Abstract]
9. Buettner, R., L. B. Mora, and R. Jove. 2002. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res. 8:945-954.
10. Calo, V., M. Migliavacca, V. Bazan, M. Macaluso, M. Buscemi, N. Gebbia, and A. Russo. 2003. STAT proteins: from normal control of cellular events to tumorigenesis. J. Cell. Physiol. 197:157-168.[CrossRef][Medline]
11. Cantley, L. C., K. R. Auger, C. Carpenter, B. Duckworth, A. Graziani, R. Kapeller, and S. Soltoff. 1991. Oncogenes and signal transduction. Cell. 64:281-302.[CrossRef][Medline]
12. Chang, B. Y., R. A. Harte, and C. A. Cartwright. 2002. RACK1: a novel substrate for the Src protein-tyrosine kinase. Oncogene 21:7619-7629. (Erratum, 22:1748.)[CrossRef][Medline]
13. Cheatham, B., C. J. Vlahos, L. Cheatham, L.Wang, J. Blenis, and C. R. Kahn. 1994. Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70 S6 kinase, DNA synthesis, and glucose transporter translocation. Mol. Cell. Biol. 14:4902-4911.
14. Chen, C. A., and H. Okayama. 1988. Calcium phosphate-mediated gene transfer: a highly efficient transfection system for stably transforming cells with plasmid DNA. BioTechniques 6:632-638.[Medline]
15. Chen, J., H. B. Sadowski, R. A. Kohanski, and L. H. Wang. 1997. Stat5 is a physiological substrate of the insulin receptor. Proc. Natl. Acad. Sci. USA 94:2295-2300.
16. Chen, S., B. D. Spiegelberg, F. Lin, E. J. Dell, and H. E. Hamm. 2004. Interaction of Gß
with RACK1 and other WD40 repeat proteins. J. Mol. Cell Cardiol. 37:399-406.[CrossRef][Medline]
17. Coffer, P. J., A. van Puijenbroek, B. M. Burgering, M. Klop-de Jonge, L. Koenderman, J. L. Bos, and W. Kruijer. 1997. Insulin activates Stat3 independently of p21ras-ERK and PI-3K signal transduction. Oncogene 15:2529-2539.[CrossRef][Medline]
18. Cox, E. A., D. Bennin, A. T. Doan, T. O'Toole, A. Huttenlocher. 2003. RACK1 regulates integrin-mediated adhesion, protrusion, and chemotactic cell migration via its Src-binding site. Mol. Biol. Cell 14:658-669.
19. Dalle, S., W. Ricketts, T. Imamura, P., Vollenweider, and J. M. Olefsky. 2001. Insulin and insulin-like growth factor I receptors utilize different G protein signaling components. J. Biol. Chem. 276:15688-15695.
20. Daris, R. J. 1993. The mitogen-activated protein kinase signal transduction pathway. J. Biol. Chem. 268:14553-14556.
21. Datta, S. R., H. Dudek, X. Tao, S. Masters, H. Fu, Y. Gotoh, and M. E. Greenberg. 1997. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91:231-241.[CrossRef][Medline]
22. DeChiara, T. M., E. J. Robertson, and A. Efstratiadis. 1991. Parental imprinting of the mouse insulin-like growth factor II gene. Cell 64:849-859.[CrossRef][Medline]
23. Decker, T., and P. Kovarik. 2000. Serine phosphorylation of STATs. Oncogene 19:2628-2637.[CrossRef][Medline]
24. Denley, A., J. C. Wallace, L. J. Cosgrove, and B. E. Forbes. 2003. The insulin receptor isoform exon 11 (IR-A) in cancer and other diseases: a review. Horm. Metab. Res. 35:778-785.[CrossRef][Medline]
25. Ebina, Y., L. Ellis, K. Jarnagin, M. Edery, L. Graf, E. Clauser, J. H. Ou, F. Masiarz, Y. W. Kan, and I. D. Goldfine. 1985. The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signaling. Cell 40:747-758.[CrossRef][Medline]
26. Graham, F. L., and A. J. Van Der Eb. 1973. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52:456-457.[CrossRef][Medline]
27. Gray, S. G., I. Stenfeldt Mathiasen, and P. De Meyts. 2003. The insulin-like growth factors and insulin-signalling systems: an appealing target for breast cancer therapy? Horm. Metab. Res. 35:857-871.[CrossRef][Medline]
28. Haro, T., K.Shimoda, H. Kakumitsu, K. Kamezaki, A. Numata, F. Ishikawa, Y. Sekine, R. Muromoto, T. Matsuda, and M. Harada. 2004. Tyrosine kinase 2 interacts with and phosphorylates receptor for activated C kinase-1, a WD motif-containing protein. J. Immunol. 173:1151-1157.
29. He, D. Y., A. J. Vagts, R. Yaka, and D. Ron. 2002. Ethanol induces gene expression via nuclear compartmentalization of receptor for activated C kinase 1. Mol. Pharmacol. 62:272-280.
30. Hermanto, U., C. S. Zong, W. Li, and L. H. Wang. 2002. RACK1, an insulin-like growth factor I (IGF-I) receptor-interacting protein, modulates IGF-I-dependent integrin signaling and promotes cell spreading and contact with extracellular matrix. Mol. Cell. Biol. 22:2345-2365.
31. Horvath, C. M., Z. Wen, and J. E. Darnell. 1995. A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain. Genes Dev. 9:984-994.
32. Jong, S.-M. J., and L.-H. Wang. 1987. The transforming protein P68gag-ros of avian sarcoma virus UR2 is a transmembrane protein with the gag portion protruding extracellularly. Oncogene Res. 1:7-21.[Medline]
33. Kahn, C. R., and M. F. White,. 1988. The insulin receptor and the molecular mechanism of insulin action. J. Clin. Investig. 82:151-156.
34. Kayali, A. G., J. Eichhorn, T. Haruta, A. J. Morris, J. G. Nelson, P. Vollenweider, J. M. Olefsky, and N. J. Webster. 1998. Association of the insulin receptor with phospholipase C-
(PLC
) in 3T3-L1 adipocytes suggests a role for PLC
in metabolic signaling by insulin. J. Biol. Chem. 273:13808-13818.
35. Kiely, P. A., M. Leahy, D. O'Gorman, and R. O'Connor. 2005. RACK1-mediated integration of adhesion and insulin-like growth factor I (IGF-I) signaling and cell migration are defective in cells expressing an IGF-I receptor mutated at tyrosines 1250 and 1251. J. Biol. Chem. 280:7624-7633.
36. Kiely, P. A., A. Sant, and R. O'Connor. 2002. RACK1 is an insulin-like growth factor 1 (IGF-1) receptor-interacting protein that can regulate IGF-1-mediated Akt activation and protection from cell death. J. Biol. Chem. 277:22581-22589.
37. Kubota, T., N. Yokosawa, S. Yokota, and N. Fujii. 2002. Association of mumps virus V protein with RACK1 results in dissociation of STAT-1 from the alpha interferon receptor complex. J. Virol. 76:12676-12682.
38. Le, M. N., R. A. Kohanski, L. H. Wang, and H. B. Sadowski. 2002. Dual mechanism of signal transducer and activator of transcription 5 activation by the insulin receptor. Mol. Endocrinol. 16:2764-2779.
39. LeRoith, D., and C. T. Roberts, Jr. 2003. The insulin-like growth factor system and cancer. Cancer Lett. 95:127-137.
40. Liu, J. P., J. Baker, A. S. Perkins, E. J. Robertson, and A. Efstratiadis. 1993. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 75:59-72.[Medline]
41. Liu, D., C. S. Zong, and L. H Wang. 1993. Distinctive effects of the carboxyl-terminal sequence of the insulin-like growth factor I receptor on its signaling functions. J. Virol. 67:6835-6840.
42. López-Bergami P., H. Habelhah, A. Bhoumik, W. Zhang, L. H. Wang, and Z. Ronai. Receptor for activated C kinase 1 (RACK1) mediates activation of Jun N-terminal Kinase (JNK) by protein kinase C. Mol. Cell 19:309-320. (Erratum, 19:578-579.)
43. Mamidipudi, V., J. Zhang, K. C. Lee, and C. A. Cartwright. 2004. RACK1 regulates G1/S progression by suppressing Src kinase activity. Mol. Cell. Biol. 24:6788-6798.
44. McCahill, A., J. Warwicker, G. B. Bolger, M. D. Houslay, and S. J. Yarwood. 2002. The RACK1 scaffold protein: a dynamic cog in cell response mechanisms. Mol. Pharmacol. 62:1261-1273.
45. Mochly-Rosen, D., B. L. Smith, C. H. Chen, M. H. Disatnik, and D. Ron. 1995. Interaction of protein kinase C with RACK1, a receptor for activated C-kinase: a role in beta protein kinase C mediated signal transduction. Biochem. Soc. Trans. 23:596-600.[Medline]
46. Niu, G., K. L. Wright, M. Huang, L. Song, E. Haura, J. Turkson, S. Zhang, T. Wang, D. Sinibaldi, D. Coppola, R. Heller, L. M. Ellis, J. Karras, J. Bromberg, D. Pardoll, R. Jove, and H. Yu. 2002. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21:2000-2008.[CrossRef][Medline]
47. O'Connor, R. 2003. Regulation of IGF-I receptor signaling in tumor cells. Horm. Metab. Res. 35:771-777.[CrossRef][Medline]
48. Schlessinger, J. 2000. Cell signaling by receptor tyrosine kinases. Cell 103:211-225.[CrossRef][Medline]
49. Scimeca, J. C., R. Ballotti, T. T. Nguyen, C. Filloux, and E. Van Obberghen. 1991. Tyrosine and threonine phosphorylation of an immunoaffinity-purified 44-kDa MAP kinase. Biochemistry 30:9313-9319.[CrossRef][Medline]
50. Skolnik, E. Y., A. Batzer, N. Li, C. H. Lee, E. Lowenstein, M. Mohammadi, B. Margolis, and J. Schlessinger. 1993. The function of GRB2 in linking the insulin receptor to Ras signaling pathways. Science 260:1953-1955.
51. Storz, P., H. Doppler, K. Pfizenmaier, and G. Muller. 1999. Insulin selectively activates STAT5b, but not STAT5a, via a JAK2-independent signalling pathway in Kym-1 rhabdomyosarcoma cells. FEBS Lett. 464:159-163.[CrossRef][Medline]
52. Thornton, C., K. C. Tang, K. Phamluong, K. Luong, A. Vagts, D. Nikanjam, R. Yaka, and D. Ron. 2004. Spatial and temporal regulation of RACK1 function and N-methyl-D-aspartate receptor activity through WD40 motif-mediated dimerization. J. Biol. Chem. 279:31357-31364.
53. Turkson, J., T. Bowman, R. Garcia, E. Caldenhoven, R. P. De Groot, and R. Jove. 1998. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol. Cell. Biol. 18:2545-2552.
54. Usacheva, A., R. Smith, R. Minshall, G. Baida, S. Seng, E. Croze, and O. Colamonici. 2001. The WD motif-containing protein receptor for activated protein kinase C (RACK1) is required for recruitment and activation of signal transducer and activator of transcription 1 through the type I interferon receptor. J. Biol. Chem. 276:22948-22953.
55. Uttamsingh, S., C. S. Zong, and L. H. Wang. 2003. Matrix-independent activation of phosphatidylinositol 3-kinase, Stat3, and cyclin A-associated Cdk2 is essential for anchorage-independent growth of v-Ros-transformed chicken embryo fibroblasts. J. Biol. Chem. 278:18798-18810.
56. Van Obberghen, E., V. Baron, L. Delahaye, B. Emanuelli, N. Filippa, S. Giorgetti-Peraldi, P. Lebrun, I. Mothe-Satney, P. Peraldi, S. Rocchi, D. Sawka-Verhelle, S. Tartare-Deckert, and J. Giudicelli. 2001. Surfing the insulin signaling web. Eur. J. Clin. Investig. 31:966-977.[CrossRef][Medline]
57. Van Obberghen, E. 1994. Signalling through the insulin receptor and the insulin-like growth factor-I receptor. Diabetologia. Suppl. 2:S125-S134.
58. Wall, M. A., D. E. Coleman, E. Lee, J. A. Iniguez-Lluhi, B. A. Posner, A. G. Gilman, and S. R. Sprang. 1995. The structure of the G protein heterotrimer Gi
1ß1
2. Cell 83:1047-1058.[CrossRef][Medline]
59. Wang, Q., R. Somwar, P. J. Bilan, Z. Liu, J. Jin, J. R. Woodgett, and A. Klip. 1999. Protein kinase B/Akt participates in GLUT4 translocation by insulin in L6 myoblasts. Mol. Cell. Biol. 19:4008-4018.
60. Wilden, P. A., and C. R. Kahn. 1994. The level of insulin receptor tyrosine kinase activity modulates the activities of phosphatidylinositol 3-kinase, microtubule-associated protein, and S6 kinases. Mol. Endocrinol. 8:558-567.[Abstract]
61. Xiong, Q., J. L.-K. Chan, C. Zong, and L.-H. Wang. 1996. Two chimeric receptors of epidermal growth factor receptor and c-Ros that differ in their transmembrane domains have opposite effects on cell growth. Mol. Cell. Biol. 16:1509-1518.[Abstract]
62. Zeng, L., P. Sachdev, L. Yan, J. L. Chan, T. Trenkle, M. McClelland, J. Welsh, and L. H. Wang. 2000. Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase activity, modulates cell morphology, and induces cell transformation. Mol. Cell. Biol. 20:9212-9224.
63. Zong, C. S., J. Chan, D. E. Levy, C. Horvath, H. B. Sadowski, and L. H. Wang. 2000. Mechanism of STAT3 activation by insulin-like growth factor I receptor. J. Biol. Chem. 275:15099-15105.
This article has been cited by other articles:
| ||||||||||||||